Biostatistics

From early study design to final reporting, we support every stage with a structured, pragmatic approach, ensuring consistency, accuracy and regulatory alignment.

Statistical Analysis Plan (SAP) development

Clear, complete and submission-ready SAPs that define the analysis upfront and avoid ambiguity later in the process.

Statistical analysis and reporting

Accurate, reproducible analyses with outputs that are easy to interpret and ready for decision-making and submission.

ISS and ISE analyses

Integrated summaries that are consistent, well-structured and aligned across studies to support regulatory review.

Biomarker analysis

Robust evaluation of biomarkers, with a focus on clinical relevance and correct interpretation of complex data.

Bayesian statistics

Flexible modelling approaches to support adaptive designs and more informed decision-making during the study.

Futility analysis

Early assessment of study viability to avoid unnecessary continuation of non-promising trials.

PK/PD modelling

Insight into drug profile and response, supporting dose selection and study optimisation.
Quality of life scale development
Development and validation of endpoints that capture patient-relevant outcomes in a reliable way.

Regulatory alignment

Analyses and documentation aligned with expectations from EMA and FDA, reducing risk during submission and review.

Common challenges we help to prevent

• Unclear or inconsistent analysis plans
• Delays in data readiness and analysis timelines
• Results that are difficult to interpret or explain
• Misalignment with regulatory bodies

The result

You get statistically sound results that are clear, reproducible and ready for submission. This strengthens the credibility of your study and supports confident decision-making at every stage.

How we work

We work closely with your team, keeping communication direct and efficient. You can expect a structured approach, early ownership and a team that understands both the detail and the broader study context.